The discovery of epidermal growth factor receptor (EGFR) driver mutation has led to a dramatic paradigm shift in the therapeutic strategies for advanced non-small-cell lung cancer (NSCLC). This evidence concerns the gene EGFR and non-small cell lung carcinoma.